Gastric Ulcers Market Report 2024

The gastric ulcers market size has grown strongly in recent years. It will grow from $4.07 billion in 2023 to $4.29 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth during the historical period can be attributed to several factors, the rising prevalence of Helicobacter pylori infections, the increasing use of nonsteroidal anti-inflammatory drugs (NSAIDs), the global growth of the geriatric population, rising awareness campaigns for gastric ulcer prevention, and the increasing incidence of stress-related disorders.

The gastric ulcers market size is expected to see strong growth in the next few years. It will grow to $5.34 billion in 2028 at a compound annual growth rate (CAGR) of 5.6%. Growth in the forecast period can be attributed to improvements in diagnostic techniques, the adoption of unhealthy dietary habits, advancements in treatment options such as proton pump inhibitors (PPIs), an aging population contributing to a higher disease burden, and the expansion of healthcare infrastructure in emerging markets. Major trends during this period include a shift towards combination therapies for enhanced efficacy, a growing preference for minimally invasive treatment procedures, the integration of digital health solutions in disease management, rising demand for over-the-counter (OTC) ulcer medications, and the expansion of personalized medicine approaches in ulcer treatment.

The growth of the gastric ulcers market is being driven by the increasing geriatric population. This demographic, typically individuals aged 65 and older, experiences specific health challenges related to aging. Advances in healthcare, resulting in longer life expectancy and declining birth rates, are contributing to the rise in the geriatric population globally. Gastric ulcers are particularly prevalent among the elderly due to higher use of NSAIDs and reduced mucosal protection, leading to greater risk of complications. According to the World Health Organization, the global population aged 60 and over is projected to grow significantly, from 1 billion in 2020 to 1.4 billion by 2030, and to 2.1 billion by 2050. Additionally, the number of individuals aged 80 or older is expected to triple, reaching 426 million by 2050. Consequently, the expanding geriatric population is fueling the growth of the gastric ulcers market.

Key players in the gastric ulcer market are focusing on developing innovative drugs, including generic versions of capsules, to better serve customers. Generic capsules contain active ingredients such as proton pump inhibitors (PPIs), H2-receptor antagonists, or other ulcer-healing agents used to treat or manage gastric ulcers. For example, in September 2021, Dr. Reddy's Laboratories, an India-based pharmaceutical company, launched a generic version of Librax (Chlordiazepoxide Hydrochloride and Clidinium Bromide capsules) in the US market. This launch provides patients with a more cost-effective option for treating stomach ulcers and related gastrointestinal conditions than the branded drug Librax.

In May 2022, Dr. Reddy's Laboratories partnered with HK Inno.N. Corporation to supply and commercialize Tegoprazan, a novel molecule for gastrointestinal diseases, in India and six key emerging markets. Under this partnership, HK Inno.N. will manufacture and supply Tegoprazan, while Dr. Reddy's will oversee local clinical development, registration, marketing, and sales in the licensed territories. HK Inno.N. Corporation is a South Korea-based pharmaceutical company specializing in drugs for gastric ulcers.

Major companies operating in the gastric ulcers market are Pfizer Inc., Merck & Co Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Co. Ltd, Amgen Inc., Boehringer Ingelheim, Viatris Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd, Cadila Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Yuhan Corporation, Daewoong Pharmaceutical Co. Ltd, Cadila Healthcare Ltd, Novitium Pharma LLC.

North America was the largest region in the gastric ulcers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric ulcers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gastric ulcers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastric ulcers, also known as peptic ulcers, are open sores on the stomach's inner lining caused by the corrosive action of stomach acid. They often result in burning stomach pain, indigestion, and discomfort. These ulcers typically arise from an imbalance between stomach acid, the enzyme pepsin, and the protective mucosal barrier lining the stomach and duodenum.

The primary drug classes used to treat gastric ulcers include proton pump inhibitors (PPIs), H2 antagonists, antacids, antibiotics, cytoprotective agents, and others. Proton pump inhibitors are medications that reduce stomach acid production by inhibiting the proton pump enzyme in gastric cells. Gastric ulcers can be diagnosed through stool tests, endoscopies, imaging tests, computed tomography (CT) scans, X-rays, blood tests, and other methods. Treatment routes include oral and parenteral administration, among others. Distribution channels primarily consist of hospital pharmacies, retail pharmacies, and online pharmacies, and the treatments are utilized by various end-users such as hospitals, specialty clinics, and homecare settings.

The gastric ulcers market research report is one of a series of new reports that provides gastric ulcers market statistics, including gastric ulcers industry global market size, regional shares, competitors with a gastric ulcers market share, detailed gastric ulcers market segments, market trends and opportunities, and any further data you may need to thrive in the gastric ulcers industry. This gastric ulcers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastric ulcers market consists of revenues earned by entities through barium swallow, H. pylori testing, and biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric ulcers market also includes sales of amoxicillin, clarithromycin, metronidazole, omeprazole, and lansoprazole. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.